Monitoring Haematocrit in Paediatric Patients Receiving Testosterone Therapy in Arab Countries

Hussain Alsaffar 1, Abdelhadi Habeb 2, Rasha T. Hamza 3, Asma Deeb 4

1. Child Health Department - Paediatric Endocrinology Unit, Sultan Qaboos University Hospital, Muscat, OMN 2. Paediatric Department, Prince Mohammed Bin Abdulaziz Hospital, Ministry of National Guard, Madinah, SAU 3. Faculty of Medicine, Ain Shams University, Cairo, EGY 4. Paediatric Endocrinology Department, Shaikh Shakhbout Medical City, Abu Dhabi, ARE

Abstract

Objectives
Testosterone is the main agent used to induce puberty in boys in Arab countries. It is recommended to monitor haematocrit before and during androgen replacement. However, data from single centre studies indicated that this recommendation is rarely practiced by paediatricians compared to adult physicians. The aim of this study is to evaluate the monitoring of haematocrit of patients on Testosterone therapy by paediatric endocrinologists practicing in Arab countries.

Methods
A cross-sectional study using an online survey that was sent to all members of the Arab Society for Paediatric Endocrinology and Diabetes (ASPED), who they practice in all Arab countries. The study was carried out between July and October 2019. Ethical approval was granted by ASPED council in May 2019 (MRE2019-02Q).

Results
One hundred four physicians responded to the survey from 17 countries. 81/104 (77.8%) answered the question about Testosterone monitoring (42 paediatric endocrinologists, 11 general paediatrician consultants with interest in endocrine, 16 specialists, four fellows and eight residents). Of the 81 responders 18 clinicians (22.2%) thought of monitoring the haematocrit; 15 (18.5%) thought no laboratory monitoring is needed at all.

Conclusion
The survey indicated that most paediatric endocrinologists in Arab countries do not monitor haematocrit in patients on testosterone replacement and majority are not aware that secondary erythrocytosis can result from androgen therapy. Raising the awareness on monitoring haematocrit during androgen replacement therapy is needed especially when reaching the adult dose.

Categories: Endocrinology/Diabetes/Metabolism, Pediatrics
Keywords: haematocrit, erythrocytosis, testosterone, monitoring, arab, asped

Introduction
In boys, puberty can be induced using the combination of long-term human choriogonadotropin (hCG) and follicular stimulating hormone therapy in cases of secondary hypogonadism [1,2]. Whereas, testosterone is the main used agent for inducing puberty in primary gonadal insufficiency or constitutional delay of growth and puberty. It has shown a great role in promoting linear growth and developing secondary sexual characteristics. Bone health and muscle mass are also influenced by testosterone [3]. Testosterone therapy does not affect the success of using gonadotropins in the future when fertility is desired. Testosterone is available in different formulations; Testosterone enantate or propionate or alternatively Sustanon® are given intramuscularly and they are preferred for replacement therapy due to their longer duration. Other formulations and preparations include oral testosterone undecanoate, subcutaneous testosterone injections, transdermal testosterone and topical gel. Sustanon® (which consists of a mixture of testosterone esters) is the most widely available preparation in MENA (Middle East and North Africa) region. Other preparations are infrequently available [4]. Most of the clinicians who responded to Arab Society of Paediatric Endocrinology and Diabetes’s (ASPED) survey are using 50 mg/month as a starting dose of Testosterone for puberty induction in males [5] and the dose can be escalated depends on the response.

Since testosterone has an erythropoietic effect, that could lead to polycythaemia, or erythrocytosis [6]
and annually afterwards. Details are shown in Figure 1. Sixteen others selected GnRH to be performed before induction of puberty, three months later. Three residents selected the liver function test to be checked monthly for the first year. Thirty-five clinicians (10 endocrinology consultants, two general paediatricians, three specialists and eight residents) selected to perform haematological and biochemical monitoring. Nineteen clinicians (11 endocrinologists, by which, only 26% of total 42 responding endocrinologists to this question, are monitoring the haematocrit. Of them, 11 endocrinologists, by which, only 26% of total 42 responding endocrinologists to this question, are monitoring the haematocrit. Of them, 11 endocrinologists, by which, only 26% of total 42 responding endocrinologists to this question, are monitoring the haematocrit. Out of 42 paediatric endocrinologists, 11 general paediatrician consultants with special interest in paediatric endocrinology, 16 specialists, four fellows and eight residents). Only 18 (22.2%) of the respondents to this question, thought of monitoring the haematocrit monitoring in paediatric age group without further specification. Overall, there is a paucity of studies describing the safety and monitoring of the testosterone therapy’s adverse events when used in paediatric age groups. Lucas-Herald et al. from Glasgow wrote about their experience of using testosterone in treating boys with hypogonadism, highlighting that generally the monitoring of testosterone safety in pediatrics is poor and not standardised, only 6% of their patients had their haematocrit checked during testosterone therapy. On the other side, Vogiatzi et al. suggested monitoring for polycythaemia in adolescents only when reaching adult testosterone dose as the response of haemoglobin to testosterone administration is dose-dependent. Our study aims to explore the experience and awareness of clinicians practicing paediatric endocrinology in Arab countries about monitoring haematocrit of their patients who are receiving testosterone therapy.

Materials And Methods

Study design

An online survey using a commercial website (Survey Monkey, USA) about puberty induction was sent out to practicing physicians in Arab countries according to the Arab Society of Paediatric Endocrinology and Diabetes (ASPED) database. The study was approved by the ASPED council for which ethical approval was granted. An invitation link was emailed, and responses were collected between July and October 2019. Respondents had the right to decline participation and data were collected anonymously.

The questionnaire

After the demographic questions, clinicians were asked about monitoring the safety of androgens when used for induction of puberty and thereafter as a replacement therapy. Different options of relevant and irrelevant laboratory investigations were provided in the survey and responders were asked to select their choice of investigations. The survey’s language was English, the official language of communication between paediatric endocrinologists in the region.

Statistical analysis

Data got summarised anonymously using descriptive statistics. p-value was calculated using z-score calculator from social science statistics, p-value less than 0.05 was considered statistically significant.

Results

In total, 104 physicians from 17 countries (Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Tunisia, United Arab Emirates and Yemen) agreed to participate. Ninety-three would use testosterone to induce puberty. Of these, 80.6% (75/93) prefer intramuscular preparation for induction and 66/93 (70.9%) use it for maintenance as a replacement. Out of the 104 participants, 81 (77.9%) responded to the raised question about safety monitoring of testosterone (42 paediatric endocrinologists, 11 general paediatrician consultants with special interest in paediatric endocrinology, 16 specialists, four fellows and eight residents). Only 18/81 (22.2%) of the respondents to this question, thought of monitoring the haematocrit. Of them, 11 endocrinologists, by which, only 26% (11/42) of the total 42 responding endocrinologists to this question, monitoring the haematocrit. 15/81 respondents from seven countries (18.5%) thought no haematological or biochemical monitoring are needed. 18/81 clinicians (10 endocrinologist consultants, two general paediatricians, three specialists and three residents) selected the liver function test to be checked monthly for the first year. 35/81 selected to monitor testosterone level before induction and then every three months. 18 selected LH and FSH on three monthly basis and 16 others selected GnRH to be performed before induction of puberty, three months later and annually afterwards. Details are shown in Figure 1.
FIGURE 1: Responses of clinicians to the question about the required laboratory investigations for monitoring when giving androgens for long term (81 clinicians responded to this question, more than one answer can be selected by each respondent).

Table 1 summarises the comparison of the responses received from endocrinologists versus others (general paediatrician with interest in endocrine, specialists, residents, and fellows). "No monitoring" option was opted more by the endocrinologists’ group with a statistical significance (p: 0.007) whereas, the others’ group chose to monitor testosterone levels monthly, more than the endocrinologists (p: 0.01).

| Test                                                                 | Endocrinologists (n = 42) | Others (n = 39) | Total responses | p-value |
|---------------------------------------------------------------------|---------------------------|----------------|----------------|---------|
| LH and FSH every three months                                       | 7                         | 11             | 18             | 0.1     |
| Testosterone level before induction and then monthly               | 13                        | 22             | 35             | 0.01    |
| Haematocrit and haemoglobin before treatment, every three months of the first year and yearly thereafter | 11                        | 7              | 18             | 0.18    |
| Liver function test monthly for the first year                     | 10                        | 8              | 18             | 0.36    |
| GnRH test before treatment, three months after induction and then annually | 8                         | 7              | 15             | 0.44    |
| No monitoring                                                      | 12                        | 3              | 15             | 0.007   |

TABLE 1: Comparison between answers of endocrinologists versus others (general paediatricians with interest in endocrine, specialists, fellows, and residents). Respondents were able to select more than one option.

LH: luteinizing hormone; FSH: follicle-stimulating hormone.

Discussion

Choosing the medicine and formulation for induction of puberty in males is usually depending on the availability, cost, convenience, and familiarity [28]. Testosterone is very widely used worldwide, and it is the most used agent in ASPED countries for puberty induction [5]. The monitoring of Testosterone therapy needs standardisation in paediatrics [25]. Stancampiano et al [29] suggested the monitoring of Testosterone therapy should be determined by the underlying pathology or the intention duration of Testosterone replacement whether it is temporary as in Constitutional Delay of Growth and Puberty (CDGP) or permanent as in hypogonadism. Laboratory investigations including full blood count (FBC) and LFT were recommended at baseline whether temporary or permanent plan of testosterone replacement. Furthermore, in patients with hypogonadism, it was recommended monitoring the FBC (Haemoglobin and haematocrit) and total
testosterone at 3, 6, 12 months, then annually for FBC and 6monthly for testosterone. Lipid profile, bone age and bone mineral density (BMD) to be checked at baseline, 12 months and then every one to two years [29].

In this survey, the question focused on the monitoring the safety and pharmacokinetics of Testosterone therapy in boys with hypogonadism whom requiring testosterone for longer than just induction over a period of three to six months. We have observed variation of clinical practice among clinicians in ASPED countries, regarding the selection of the appropriate laboratory investigations for monitoring. Comparing our results with previous studies, haematocrit considered to be checked by 18/81 (22.2%) of our respondents. Whereas a retrospective study at Boston Children’s Hospital between 2006 and 2013, revealed that haematocrit was checked in 41/59 (69.5%) adolescents and young adults [30]. Another retrospective study from Royal Hospital for Children in Glasgow, between 2012 and 2017 showed haematocrit was checked in 6/46 (13%) (Table 2) [24]. There is a great potential to improve this practice, considering the other recommended investigations such as bone age and DEXA scan for BMD. Our survey focused only on the laboratory investigations, which gave the study some limitations.

| Study               | Population                          | (n)   | Hct monitoring during Testosterone therapy |
|---------------------|-------------------------------------|-------|------------------------------------------|
| Nahata et al (2015) | Adolescents and young adults aged ≥ 16 years | 59    | (41/59) 69%                             |
| Lucas-Herald (2018) | Adolescents (12.1 to 17.7 years)     | 46    | (6/46) 13%                              |
| Our study           | Clinicians were asked                | 81    | (18/81) 22.2%                           |

TABLE 2: Summary of previous relevant studies compared to ASPED clinicians’ practice.

ASPED: Arab Society for Paediatric Endocrinology and Diabetes.

To our knowledge erythrocytosis was not reported in adolescents as a complication of Testosterone therapy in our region, but whether that is because of lack of awareness, hence under reporting, or because of the rarity of this complication in youngsters. Further studies are deemed necessary, but first we will aim to raise the awareness of clinicians in our region about the recommended scheme of investigations [29], followed by a prospective study to give a better insight.

Other options for selection that were provided in the survey included FSH and LH monitoring. This could be justifiable in patients with primary gonadal failure receiving replacement therapy to examine the effect of androgen on suppressing the gonadotrophs, but not for hypogonadotrophic hypogonadism, where it is only recommended as a baseline investigation.

Liver function was suggested to be monitored six-monthly, to screen for transaminitis [31]. However, the Endocrine Society did not recommend monitoring liver function test in its most recent guideline. In fact, it was considered unnecessary investigations for men taking intramuscular injections or transdermal preparations as these forms are not associated with liver dysfunction [32]. Rather, it is only suggested to be checked at baseline, 6-12 months and as warranted clinically for patients using oral alkylated agents [33] which we do not use frequently in our region.

Measurement of testosterone level is suggested 6-12 weeks after initiation of the replacement therapy, and for those patients receiving injectable forms (testosterone enanthate or cypionate) to have an earlier measurement of serum testosterone at one to two weeks after commence ment of therapy [34]. But we were not expecting 35 clinicians to consider a monthly testosterone level measurement!

Lastly, GnRH test is neither justifiable nor recommended for monitoring patients on testosterone. In fact, we are surprised that 16/81 (19.8%) would perform this test 3 months after starting treatment and yearly thereafter. This could be just a waste of resources, creating unnecessary anxiety and patients’ discomfort. We could not see any justification for conducting GnRH for patients on Testosterone therapy, hence the surprise that we had when it was selected.

Conclusions

The authors would recommend standardisation of testosterone therapy monitoring in ASPED countries. Haematocrit and total testosterone level checking at baseline, three-monthly for the first year, followed by annual FBC and six-monthly total testosterone level. When there is no evidence of transaminitis at the baseline, liver function tests to be monitored only for patients on oral alkylated agents. Lipid profile, DEXA scan and bone age to be done at baseline and 1-2 yearly thereafter. By which, this will ensure the achievement of patient comfort, as well as time and resources savings by minimising the unnecessary investigations and over medicalisation. Long-term prospective study is recommended in our region to
evaluate the prevalence of erythrocytosis in people younger than 20 years of age.

### Additional Information

#### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. Arab Society of Paediatric Endocrinology and Diabetes (ASPED) has been found an acceptable research project and therefore approval is granted. We wish you a productive study with your research work. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### References

1. Barrio R, de Luis D, Alonso M, Lamas A, Moreno JC: Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril. 1999, 71:244-8. 10.1016/S0015-0282(98)00450-6
2. Zacharin M, Sabin MA, Nair VV, Dabudghao P: Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. Fertil Steril. 2012, 98:836-42. 10.1016/j.fertnstert.2012.06.022
3. Yin A, Swerdlow R: Treating hypogonadism in younger males. Expert Opin Pharmacother. 2010, 11:1529-40. 10.1517/14656561.1003742947
4. Deeb A, Alsaffar H, Hamza RT, Habea A: Availability of medications used for puberty induction and maintenance in adolescents with hypogonadism in the Arab region. bioRxiv. 2020, 10.1101/2020.10.27.356008
5. Hamza RT, Deeb A, Alsaffar H, Alani SH, Habea A: Timing and regimen of puberty induction in children with hypogonadism: a survey on the practice in Arab countries. J Pediatr Endocrinol Metab. 2020, 33:1197-202. 10.1515/jpem-2020-0157
6. Ohlander SJ, Varghese B, Pastuszak AW: Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2018, 6:77-85. 10.1016/j.xsmr.2017.04.001
7. de Swart S, J van der Heide HD, van der Luchte JM, et al.: Treatment of pubertal delay in female transgender persons by starting replacement therapy with 17β-estradiol and spironolactone. Horm Res Paediatr. 2022, 97:15-22. 10.1159/000513512
8. Zargar S, Al-Majali SG, Al-Sheikh MA, et al.: Prevalence of polycythaemia with different formulations of testosterone therapy in transmaxculine individuals. Intern Med J. 2021, 51:879-8. 10.1111/imj.14829
9. Ejaz SS, Hagberg KW: The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UK-based general practice research database. Br J Clin Pharmacol. 2015, 75:260-70. 10.1111/bcp.12523.x
10. Dohs AS, Wayne-Meikle A, Arver S, Sanders SW, Caramelli KE, Mazer NA: Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999, 84:3469-78. 10.1210/jcem.84.10.6070
11. Rhasis S, Brito IP, Cunningham GR, et al.: Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018, 103:1715-44. 10.1210/jc.2018-00229
12. Yeap BB, Grossmann M, McLachlan RI, et al.: Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. Med J Aust. 2016, 205:228-31. 10.5694/mja16.00448
13. Nolan BJ, Leemage SY, Ooi O, et al.: Prevalence of polycythaemia with different formulations of testosterone therapy in transmaxculine individuals. Intern Med J. 2021, 51:879-8. 10.1111/imj.14829
14. Rotker KL, Alaviam M, Nelson B, Baird GL, Miner MM, Sigman M, Hwang K: Addition of recombinant follicle-stimulating hormone to developing secondary polycythemia. J Sex Med. 2017, 14:1297-303. 10.1016/j.jsxm.2020.05.006
15. Kaminiatzi KC, McCollough A, Hwang K, Jaffe JS, Wang C, Swerdloff RS: A 52-week study of dose adjusted subcutaneous testosterone enanthate in oil self-administered via disposable auto-injector. J Urol. 2019, 201:587-94. 10.1016/j.juro.2018.09.057
16. Cervi A, Balitsky AK: Testosterone use causing erythrocytosis. CMAJ. 2017, 189:E1286-8. 10.1542/cmaaj.15.10103
17. Choy DM, Voon LW, Teoh SC: Unusual cause of branch retinal artery occlusion: Polycythemia in a transgender man from unregulated testosterone use. Retin Cases Brief Rep. 2019, 10.1097/ICR.0000000000000924
18. Low MS, Vilcassim S, Fedele P, Grigoriadis G: Anabolic androgenic steroids, an easily forgotten cause of polycythemia and cerebral infarction. Intern Med J. 2016, 46:497-9. 10.1111/imj.13029
19. Tikka T, Mistry N, Janjua A: Acute unilateral sensorineural hearing loss associated with anabolic steroids and polycythemia: case report. J Laryngol Otol. 2016, 130:509-13. 10.1017/S0022215115005187
20. Lundy SD, Parekh NV, Shokes DA: Obstructive sleep apnea is associated with polycythemia in hypogonadal men on testosterone replacement therapy. J Sex Med. 2020, 17:1297-305. 10.1016/j.jsxm.2020.05.006

2021 Alsaffar et al. Cureus 13(8): e17618. DOI 10.7759/cureus.17618
21. Kavoussi PK, Machen GL, Werzsel JL, Ellis AM, Kavoussi M, Kavoussi KM, Kavoussi SK: Medical treatments for hypogonadism do not significantly increase the risk of deep vein thrombosis over general population risk. Urology. 2019, 124:127-30. 10.1016/j.urology.2018.11.009
22. Van Buren NL, Hove AJ, French TA, Gorlin JB: Therapeutic phlebotomy for testosterone-induced polycythemia. Am J Clin Pathol. 2020, 154:53-7. 10.1093/ajcp/aqaa019
23. BNFC - Medicines Complete. (2020). Accessed: 28-03-2020: https://www.medicinescomplete.com/#/content/bnfc/_593379312?hspl=Testosterone.
24. EMC - Medicines. (2020). Accessed: 01-07-2020: https://www.medicines.org.uk/emc/product/3733/smpc#CLINICAL_PRECAUTIONS.
25. Lucas-Herald AK, Mason E, Beaumont P, Mason A, Shaikh MG, Wong SC, Ahmed SF: Single-centre experience of testosterone therapy for boys with hypogonadism. Horm Res Paediatr. 2018, 90:123-7. 10.1159/000490738
26. Vogiatzi M, Tursi JP, Jaffe JS, Hobson S, Rogol AD: Testosterone use in adolescent males: current practice and unmet needs. J Endocr Soc. 2021, 5:bvaa161. 10.1210/jendo/bvaa161
27. socscistatistics. (2020). Accessed: 29/11/2020: https://www.socscistatistics.com/tests/ztest/default2.aspx..
28. Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD: Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust. 2000, 172:220-4. 10.5694/j.1326-5377.2000.tb129115.x
29. Stancampiano MR, Lucas-Herald AK, Russo G, Rogol AD, Ahmed SF: Testosterone therapy in adolescent boys: the need for a structured approach. Horm Res Paediatr. 2019, 92:215-28. 10.1159/000504670
30. Nahata L, Yu RN, Bhasin S, Cohen LE: Management of testosterone therapy in adolescents and young men with hypogonadism: are we following adult clinical practice guidelines?. J Pediatr Endocrinol Metab. 2015, 28:335-40. 10.1515/jped-2014-0134
31. Collins-Bride G, Saxe J: Clinical Guidelines for Advanced Practice Nursing: An Interdisciplinary Approach. Jones and Bartlett Learning, USA; 2013.
32. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004, 350:482-92. 10.1056/NEJMra022251
33. Seftel A: Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res. 2007, 19:2-24. 10.1038/sj.ijir.3901566
34. Carnegie C: Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev Urol. 2004, 6:S3-8.